Movement Disorders

Just over half (53%) of patients treated with the amantadine extended-release agent had greater than 50% reduction in time spent ON with dyskinesia and just over a quarter (27%) of patients had greater than 75% reduction.

Dosing will be paused in the open-label extension study (GEN-EXTEND) of tominersen while data are carefully analyzed to inform next steps on this study.

The SNP-targeting agents showed no evidence of dose response in PRECISION-HD2 and similar results in PRECISION-HD1, though development of SNP3-targeted agent WVE-003 in HD will continue.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 26, 2021.

Here's what is coming soon to NeurologyLive.

The chief scientific officer of the Parkinson’s Foundation discussed the “PD GENEration” study that offers genetic testing and counseling to 15,000 people with Parkinson disease.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 19, 2021.

Here's what is coming soon to NeurologyLive.

Students share their experience in the virtual classroom, navigating new requirements, and the lessons learned from their position in a global pandemic.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 12, 2021.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Stewart Factor, DO.

The chief scientific officer of the Parkinson’s Foundation also talked about the recent PD Health @ Home series created by the foundation.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 5, 2021.

Genetically-index TNF-TNFR1 signaling blockade predicted reduced risk of Crohn disease and ulcerative colitis, and increased multiple sclerosis risk.

Additionally, the therapy’s developer Yumanity Therapeutics announced the results of a single ascending dose study and enrollment in a multiple ascending dose study.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 26, 2021.

Tavapadon’s rare combination of efficacy and minimal adverse effects may indicate a step forward in the treatment of Parkinson disease.

Here's what is coming soon to NeurologyLive.

Bijan Nejadnik, MD, chief medical officer, SanBio, also thanked neurological experts that collaborated on the phase 2 STEMTRA trial.

The chief scientific officer of the Parkinson’s Foundation discussed the importance of screening for mood disturbances in patients with PD.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 19, 2021.

Masahito Kawabori, MD, PhD, associate professor, Hokkaido University, discussed results of the phase 2 STEMTRA trial.